Events on 27 September 2023
CONGRESS 2023 - CE and UKCA certification – what they mean and the implications for pathology
27/09/2023
There are complex regulatory changes taking place across the UK and the EU, which could have a significant impact on laboratory services. This session will cover what you need to know to keep on top of this and know what actions you should be taking for compliance.
CONGRESS 2023 - Kell Blood Group System
27/09/2023
If you're interested in blood groups, blood group serology, transfusion or just want to know "what the hell is Kell?" then this talk is for you...
This presentation on the Kell Blood group system will cover the following;
An entertaining overview of the Kell blood group system
Structure, function and molecular background of the most well-known Kell blood group system antigens
Clinical significance of antibodies to Kell blood group system antigens
The association with the Kx blood group system
Interesting facts about the lesser known Kell Blood group system antigens
This presentation on the Kell Blood group system will cover the following;
An entertaining overview of the Kell blood group system
Structure, function and molecular background of the most well-known Kell blood group system antigens
Clinical significance of antibodies to Kell blood group system antigens
The association with the Kx blood group system
Interesting facts about the lesser known Kell Blood group system antigens
CONGRESS 2023 - Who lives in a papaya under the sea? SpongeBob Alloadsorption Pants! A Transfusion Laboratory Perspective of AIHA
27/09/2023
Who lives in a papaya under the sea? SpongeBob Alloadsorption Pants! A Transfusion Laboratory Perspective of AIHA
CONGRESS 2023 - International Blood Group Reference Laboratory (IBGRL) - Finding New Blood Groups
27/09/2023
Explanation of the various serological and molecular techniques that are available to identify novel blood groups. Discussing how these cases may present within the hospital and RCI labortories through to publication and ratification at the International Society of Blood Transfusion.
CONGRESS 2023 - Antibody Workshop
27/09/2023
Join some of our panel members for our lunchtime session where we will be hosting an antibody workshop. Looking at different types of antibodies and how to positively identify or eliminate any suspected clincially significant antibodies, whilst testing your knowledge and skills.
The aim is to make the session fun and interactive, focusing on some top tips for solving those antibody mysteries.
The aim is to make the session fun and interactive, focusing on some top tips for solving those antibody mysteries.
CONGRESS 2023 - Managing blood stocks in a shortage
27/09/2023
In 2022 the unthinkable happened - NHSBT was forced to declare an Amber Alert for red cells in England. But does that tell the whole story? This presentation will briefly examine the build-up to the shortage declaration but also consider its impact, provide evidence of the response within hospitals and consider the opportunities for future change in practices.
CONGRESS 2023 - Production of platelets and red cell in vitro for human transfusion
27/09/2023
The idea of generating blood cells in vitro for transfusion is not new but only now we are reaching the point where the concept is reaching clinical trials. In vitro derived blood cells (namely platelets and red cells at this stage) are complementary to blood donor-derived products but with distinct advantages: biological safety, more resilient supply line and potentially less immunogenicity.
We have developed a forward programming approach relying on the overexpression of transcription factors in pluripotent stem cells to produce the platelet mother cells, the megakaryocytes, conferring added efficiency and purity to the culture system. The challenges that remain to be addressed are related to transition to GMP production, optimising platelet release in the culture and quality control of the final product. The power of genome editing has also allowed us to explore the production of platelets with added clinical benefit (immune silent, added thrombotic potential).
Red cell production from primary CD34+ progenitors has been demonstrated in academic laboratories about a decade ago. We are now mid-way through a first in human study to look at the potential of using in vitro derived red cells for transfusion. One of the main benefits would be a potentially longer survival of the manufactured red cells in the circulation than their donor-derived counterpart. This would allow spacing out transfusion intervals for patients on chronic transfusion programme, thereby reducing iron overload.
We have developed a forward programming approach relying on the overexpression of transcription factors in pluripotent stem cells to produce the platelet mother cells, the megakaryocytes, conferring added efficiency and purity to the culture system. The challenges that remain to be addressed are related to transition to GMP production, optimising platelet release in the culture and quality control of the final product. The power of genome editing has also allowed us to explore the production of platelets with added clinical benefit (immune silent, added thrombotic potential).
Red cell production from primary CD34+ progenitors has been demonstrated in academic laboratories about a decade ago. We are now mid-way through a first in human study to look at the potential of using in vitro derived red cells for transfusion. One of the main benefits would be a potentially longer survival of the manufactured red cells in the circulation than their donor-derived counterpart. This would allow spacing out transfusion intervals for patients on chronic transfusion programme, thereby reducing iron overload.